220 related articles for article (PubMed ID: 35088591)
1. Disrupting Crystal Growth through Molecular Recognition: Designer Therapies for Kidney Stone Prevention.
Shtukenberg AG; Hu L; Sahota A; Kahr B; Ward MD
Acc Chem Res; 2022 Feb; 55(4):516-525. PubMed ID: 35088591
[TBL] [Abstract][Full Text] [Related]
2. Crystal growth inhibitors for the prevention of L-cystine kidney stones through molecular design.
Rimer JD; An Z; Zhu Z; Lee MH; Goldfarb DS; Wesson JA; Ward MD
Science; 2010 Oct; 330(6002):337-341. PubMed ID: 20947757
[TBL] [Abstract][Full Text] [Related]
3. Cystine growth inhibition through molecular mimicry: a new paradigm for the prevention of crystal diseases.
Lee MH; Sahota A; Ward MD; Goldfarb DS
Curr Rheumatol Rep; 2015 May; 17(5):33. PubMed ID: 25874348
[TBL] [Abstract][Full Text] [Related]
4. Role of Molecular Recognition in l-Cystine Crystal Growth Inhibition.
Poloni LN; Zhu Z; Garcia-Vázquez N; Yu AC; Connors DM; Hu L; Sahota A; Ward MD; Shtukenberg AG
Cryst Growth Des; 2017 May; 17(5):2767-2781. PubMed ID: 29234242
[TBL] [Abstract][Full Text] [Related]
5. Cystinuria: genetic aspects, mouse models, and a new approach to therapy.
Sahota A; Tischfield JA; Goldfarb DS; Ward MD; Hu L
Urolithiasis; 2019 Feb; 47(1):57-66. PubMed ID: 30515543
[TBL] [Abstract][Full Text] [Related]
6. Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria.
Goldfarb DS
Clin J Am Soc Nephrol; 2011 Aug; 6(8):2093-7. PubMed ID: 21757641
[TBL] [Abstract][Full Text] [Related]
7. Determination of specific binding interactions at L-cystine crystal surfaces with chemical force microscopy.
Mandal T; Ward MD
J Am Chem Soc; 2013 Apr; 135(15):5525-8. PubMed ID: 23557230
[TBL] [Abstract][Full Text] [Related]
8. Medicine. Stopping the stones.
Coe FL; Asplin JR
Science; 2010 Oct; 330(6002):325-6. PubMed ID: 20947749
[No Abstract] [Full Text] [Related]
9. Discovering inhibitor molecules for pathological crystallization of CaOx kidney stones from natural extracts of medical herbs.
Li S; Macaringue EGJ; Zhou D; Shi P; Tang W; Gong J
J Ethnopharmacol; 2022 Feb; 284():114733. PubMed ID: 34644589
[TBL] [Abstract][Full Text] [Related]
10. Molecular modifiers of kidney stones.
Alamani BG; Rimer JD
Curr Opin Nephrol Hypertens; 2017 Jul; 26(4):256-265. PubMed ID: 28410252
[TBL] [Abstract][Full Text] [Related]
11. Cystine crystal volume determination: a useful tool in the management of cystinuric patients.
Daudon M; Cohen-Solal F; Barbey F; Gagnadoux MF; Knebelmann B; Jungers P
Urol Res; 2003 Jul; 31(3):207-11. PubMed ID: 12748836
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and evaluation of l-cystine diamides as l-cystine crystallization inhibitors for cystinuria.
Yang Y; Albanyan H; Lee S; Aloysius H; Liang JJ; Kholodovych V; Sahota A; Hu L
Bioorg Med Chem Lett; 2018 May; 28(8):1303-1308. PubMed ID: 29571572
[TBL] [Abstract][Full Text] [Related]
13. Staghorn cystine stone in a 72-year-old recurrent calcium stone former.
Cupisti A; Farnesi I; Armillotta N; Francesca F
Clin Nephrol; 2012 Jul; 78(1):76-80. PubMed ID: 22732341
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life (HRQoL) in cystine compared with non-cystine stone formers.
Modersitzki F; Pizzi L; Grasso M; Goldfarb DS
Urolithiasis; 2014 Feb; 42(1):53-60. PubMed ID: 24253538
[TBL] [Abstract][Full Text] [Related]
15. The role of macromolecules in the formation of kidney stones.
Rimer JD; Kolbach-Mandel AM; Ward MD; Wesson JA
Urolithiasis; 2017 Feb; 45(1):57-74. PubMed ID: 27913854
[TBL] [Abstract][Full Text] [Related]
16. Do "inhibitors of crystallisation" play any role in the prevention of kidney stones? A critique.
Robertson WG
Urolithiasis; 2017 Feb; 45(1):43-56. PubMed ID: 27900407
[TBL] [Abstract][Full Text] [Related]
17. Illusory spirals and loops in crystal growth.
Shtukenberg AG; Zhu Z; An Z; Bhandari M; Song P; Kahr B; Ward MD
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17195-8. PubMed ID: 24101507
[TBL] [Abstract][Full Text] [Related]
18. [Pathophysiology, diagnosis and conservative therapy of non-calcium kidney calculi].
Hochreiter W; Knoll T; Hess B
Ther Umsch; 2003 Feb; 60(2):89-97. PubMed ID: 12649987
[TBL] [Abstract][Full Text] [Related]
19. Nucleation of calcium oxalate crystals by albumin: involvement in the prevention of stone formation.
Cerini C; Geider S; Dussol B; Hennequin C; Daudon M; Veesler S; Nitsche S; Boistelle R; Berthézène P; Dupuy P; Vazi A; Berland Y; Dagorn JC; Verdier JM
Kidney Int; 1999 May; 55(5):1776-86. PubMed ID: 10231440
[TBL] [Abstract][Full Text] [Related]
20. l-Cystine Diamides as l-Cystine Crystallization Inhibitors for Cystinuria.
Hu L; Yang Y; Aloysius H; Albanyan H; Yang M; Liang JJ; Yu A; Shtukenberg A; Poloni LN; Kholodovych V; Tischfield JA; Goldfarb DS; Ward MD; Sahota A
J Med Chem; 2016 Aug; 59(15):7293-8. PubMed ID: 27409142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
